Published in Prog Clin Biol Res on January 01, 1988
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Drug discovery: Cell lines battle cancer. Nature (2012) 1.70
Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from a freshwater species of Lyngbya isolated from the Florida Everglades. Comp Biochem Physiol C Toxicol Pharmacol (2004) 1.23
HLA class I and II genotype of the NCI-60 cell lines. J Transl Med (2005) 1.11
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery. J Nat Prod (2009) 1.09
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med (2015) 1.00
An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One (2012) 0.96
Cancer: Discrepancies in drug sensitivity. Nature (2013) 0.94
Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A (2005) 0.93
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One (2015) 0.87
Exploiting genetic complexity in cancer to improve therapeutic strategies. Drug Discov Today (2012) 0.86
Expression of microRNAs in the NCI-60 cancer cell-lines. PLoS One (2012) 0.86
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Invest New Drugs (2001) 0.85
Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis. ACS Chem Biol (2013) 0.85
Downregulation of the mitochondrial phosphatase PTPMT1 is sufficient to promote cancer cell death. PLoS One (2013) 0.84
Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. Biochem Pharmacol (2012) 0.83
In silico modeling predicts drug sensitivity of patient-derived cancer cells. J Transl Med (2014) 0.82
PTN signaling: Components and mechanistic insights in human ovarian cancer. Mol Carcinog (2014) 0.82
Animal models of human colorectal cancer: Current status, uses and limitations. World J Gastroenterol (2015) 0.80
Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. PLoS One (2015) 0.79
Synthesis and antiproliferative activity of coumarin-estrogen conjugates against breast cancer cell lines. Lett Drug Des Discov (2009) 0.78
Cell line modeling for systems medicine in cancers (review). Int J Oncol (2013) 0.78
Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery. Trends Genet (2014) 0.78
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib. PLoS One (2015) 0.78
Drug-eluting microarrays to identify effective chemotherapeutic combinations targeting patient-derived cancer stem cells. Proc Natl Acad Sci U S A (2015) 0.77
K-Ras Activation Induces Differential Sensitivity to Sulfur Amino Acid Limitation and Deprivation and to Oxidative and Anti-Oxidative Stress in Mouse Fibroblasts. PLoS One (2016) 0.75
Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer. BMC Genomics (2016) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 10.53
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest (1985) 3.40
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J Natl Cancer Inst (1994) 2.78
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
Neural computing in cancer drug development: predicting mechanism of action. Science (1992) 2.38
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst (1998) 2.31
Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature (1980) 2.30
In vivo cultivation of tumor cells in hollow fibers. Life Sci (1995) 2.29
Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol (1998) 2.19
Enzymatic epoxidation. II. Comparison between the epoxidation and hydroxylation reactions catalyzed by the -hydroxylation system of Pseudomonas oleovorans. J Biol Chem (1973) 2.16
Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother (1987) 2.11
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res (1991) 2.06
Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J Med Chem (1995) 1.98
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem (1992) 1.89
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des (1997) 1.89
Enzymatic epoxidation. I. Alkene epoxidation by the -hydroxylation system of Pseudomonas oleovorans. Biochem Biophys Res Commun (1972) 1.73
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol (1994) 1.70
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol (1998) 1.69
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol (1992) 1.68
Enhanced production of mouse mammary tumor virus in dexamethasone-treated, 5-iododeoxyuridine-stimulated mammary tumor cell cultures. J Natl Cancer Inst (1974) 1.62
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep (1986) 1.61
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst (1999) 1.61
TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol (2000) 1.60
Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol (1999) 1.57
Oxidation of 1-alkenes to 1,2-epoxyalkanes by Pseudomonas oleovorans. Appl Microbiol (1973) 1.57
In vitro system for production of mouse mammary tumor virus. Appl Microbiol (1974) 1.54
Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod (1998) 1.50
The extracellular accumulation of metabolic products by hydrocarbon-degrading microorganisms. Adv Appl Microbiol (1971) 1.49
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother (1989) 1.48
Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des (1995) 1.46
Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res (1982) 1.46
Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus materials. J Natl Cancer Inst (1975) 1.44
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1993) 1.41
Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature (1977) 1.41
Detection of natural Mycoplasma pulmonis infection in rats and mice by an enzyme linked immunosorbent assay (ELISA). Lab Anim Sci (1981) 1.41
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40
Mining and visualizing large anticancer drug discovery databases. J Chem Inf Comput Sci (2000) 1.38
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer (1990) 1.35
Isolation of separate precursor polypeptides for the mouse mammary tumor virus glycoproteins and nonglycoproteins. Virology (1978) 1.35
Plasma protein binding interaction between phenytoin and valproic acid in vitro. Br J Clin Pharmacol (1978) 1.34
Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res (1987) 1.34
2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. Br J Cancer (1998) 1.33
Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem (1991) 1.32
Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol (2001) 1.31
Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest (1995) 1.30
Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther (1980) 1.29
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29
A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J Antibiot (Tokyo) (1987) 1.29
Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther (2001) 1.28
Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod (1993) 1.26
Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res (1997) 1.26
Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin. J Med Chem (1993) 1.25
Crystal structure of Escherichia coli HdeA. Nat Struct Biol (1998) 1.25
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A (1991) 1.24
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res (2000) 1.23
Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem (1998) 1.23
Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol (2000) 1.23
Growth of Acinetobacter calcoaceticus on ethanol. Appl Microbiol (1973) 1.23
Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol (1996) 1.21